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BACKGROUND: This study aimed to compare pantoprazole, a proton-pomp inhibitors (PPIs), 
and ranitidine, a H2 receptor antagonists (H2RA), in ceasing dyspeptic symptoms in the emergency 
department (ED).
METHODS: This randomized, double-blinded study compared the effectiveness of 50 mg 
ranitidine (Ulcuran
®
) and 40 mg pantoprazole (Pantpas
®
), given in a 100 mL saline solution by an 
intravenous rapid infusion within 2–4 minutes in patients with dyspepsia presented to the ED. Pain 
intensity was measured at baseline, 30 and 60 minutes after the drug administration.
RESULTS: A total of 72 patients were eligible for the study. Of these patients, 2 were excluded 
from the study because the initial visual analogue scale (VAS) scores were under 20 mm and 4 were 
excluded from the statistical analysis because of being diagnosed as having other causes of epigastric 
pain despite being allocated to one of the study groups. Thirty-three patients in the pantoprazole group 
and 33 patients in the ranitidine group were analyzed ultimately. The mean age of the patients was 
36.6±15 years, and 26 (39.4%) patients were male. Both of the groups reduced pain effectively at 30 
[27.6±28 (18 to 37) vs. 28.3±23 (20 to 37), respectively] and 60 minutes [39.6±39 (26 to 53) vs. 42.3±25 
(33 to 51), respectively]. There were 13 (39.4%) patients in the pantoprazole group and 8 (24.2%) 
patients in the ranitidine group who required additional drug at the end of the study (P=0.186).
CONCLUSION: Intravenous pantoprazole and ranitidine are not superior to each other in 
ceasing dyspeptic symptoms at 30 and 60 minutes in the ED.
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INTRODUCTION
Dyspepsia is characterized as a discomfort or pain 
in the epigastric region that may be related to peptic 
ulcer, gastritis or functional dyspepsia, characterized 
by the negative results of endoscopy. The prevalence 
of dyspepsia in the USA is approximately 25% and the 
disease is the most common cause (6.8%) for emergency 
visits.
[1]
 The high prevalence of dyspepsia leads to not 
only the workload of physicians but also high costs.
[2,3]
Proton-pomp inhibitors (PPIs), H2 receptor antagonists 
(H2RAs) and anti-acids are the most common agents used 
for the treatment of dyspepsia, peptic ulcer and gastritis. 
A Cochrane meta-analysis reported that PPIs are more 
effective than H2 receptor blockers (RR 0.63, 95%CI 0.47 
to 0.85) and anti-acids (RR 0.72, 95%CI 0.64 to 0.80).
[4]
 
However, the DIAMOND study compared step-up (anti-
www.wjem.org
31World J Emerg Med, Vol 7, No 1, 2016
acids, H2RA and PPIs respectively) and step-down 
strategies (reverse of the step-up strategy) in patients with 
dyspepsia in primary care patients and showed that there 
was no difference in six-month treatment success between 
the two groups (72% vs. 70%) but with lower costs.
[5]
There is also little known about the effectiveness of 
PPIs and H2RAs in patients with dyspepsia presented to 
the emergency department (ED).
[6,7]
 This study aimed to 
compare pantoprazole, a PPI, and ranitidine, a H2RA, in 
ceasing dyspeptic symptoms in the ED.
METHODS
Study design and setting
This single-center prospective randomized double-
blind clinical trial was conducted between October 2012 
and January 2013 in the ED of a tertiary care hospital 
with an annual census of 90 000 patients. We compared 
the efficacy of pantoprazole and ranitidine in patients 
with dyspepsia presented to the ED. A written inform 
consent was obtained from all patients. The study was 
registered to clinicaltrials.gov (clinicaltrials.gov ID: 
NCT01737840). Both the local ethics committee and 
central health agency approved the trial.
Selection of participants
Patients over 18 years old presented with epigastric 
pain suggestive of dyspepsia with visual analogue scale 
(VAS) score of over 20 mm were eligible for the study. 
They were enrolled into the study consecutively 24 hours 
a day, 7 days a week. The exclusion criteria from the 
study were as follows: patients diagnosed as having other 
possible causes of epigastric pain such as acute cholecytitis, 
pancreatitis, myocardial infarction at the end of the ED 
period or 24 hours after the ED discharge with a telephone 
follow-up, pregnancy, patients with unstable vital signs, 
receiving anti-acids, H2 receptor blockers of PPI within one 
hour of ED visit, known allergy to the study agents, pain 
intensity with a VAS score under 20 mm, denied to give 
informed consent, and illiterate patients.
Attending physicians decided the patient eligibility 
between 08:00 and 24:00 and senior residents at the 
remaining time. The physicians were free of performing 
diagnostic tests during or after the study period for 
additional diagnosis.
Interventions
The patients received a single intravenous dose of 
40 mg pantoprazole (Pantpas
®
, Nycomed) and 50 mg 
ranitidine (Ulcuran
®
, Abfar, Istanbul, Turkey). Both drugs 
were given in a 100 mL normal saline solution with a rapid 
infusion of 2–4 minutes. An assistant blinded to the study 
prepared randomization schedule. If a patient was suitable 
for the study, the study nurse got a folded paper displaying 
a study number which was also recorded to the study form 
from an opaque bag and prepared the study drug matched 
with the number. And another nurse with a blinded fashion 
administered the study drug. Both drugs were identical in 
color and appearance. Physicians, nurses administered the 
study drugs and patients were all blinded to the study drugs.
Methods of measurement
Pain intensity was measured by a 100-mm VAS 
(bounded by "no pain" and "worst pain") before the study 
drug, 30 and 60 minutes after the drug administration. 
Patients were blinded to the previous VAS scores. 
Adverse events such as nausea, vomiting or allergic 
reaction were recorded to the study form at the end of the 
study period. Patients diagnosed with another pathology 
causing epigastric pain rather than dyspepsia during 
the ED stay and 24 hours after the ED discharge with a 
telephone follow-up were also recorded.
Outcome measures
The primary outcome measure was the pain reduction 
recorded by VAS at 30 and 60 minutes. The secondary 
outcome measures were the need for additional drugs at 
60 minutes and recurrence of pain at 24 hours after ED 
discharge.
Statistical analysis
The study data were analyzed with MedCalc 12 and 
SPSS 16.0. Because the numeric data were distributed 
normally, it was presented by mean±standard deviation 
with 95% confi dence interval (CI). The categorical data 
were presented as rates. The normality analysis was 
performed by the Kolmogorov Smirnov test. For 25 mm 
standard deviation in patients presented with dyspepsia to 
the ED and a clinically signifi cant difference of 20 mm in 
VAS, a minimum of 33 patients is needed for each group 
with 90% power. The statistical analysis was planned to 
be performed with an intention to treat analysis. All the 
hypotheses were constructed as two tailed and an alpha 
critical value of 0.05 was accepted as signifi cant.
RESULTS
Seventy-two patients were enrolled in the study. Two 
of the 72 patients were excluded from the study because 
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their initial VAS scores were under 20 mm, and 4 were 
excluded from the statistical analysis because of other 
causes of epigastric pain despite being allocated to one 
of the study groups (Figure 1). Thirty-three patients in 
the pantoprazole group and 33 patients in the ranitidine 
group were analyzed ultimately. The mean age of the 
patietns was 36.6±15 years, and 26 (39.4%) patients 
were male.
Main results
Both groups reduced pain effectively at 30 [27.6±28 
(18 to 37) vs. 28.3±23 (20 to 37), respectively] and 
60 minutes [39.6±39 (26 to 53) vs. 42.3±25 (33 to 
51), respectively] (Table 1). There was no significant 
difference in the improvement of dyspepsia at 30 [0.76 
(–12 to 13)] and 60 minutes [2.7 (–13 to 19)] between 
the two groups (Figures 2 and 3).
There were 13 (39.4%) patients in the pantoprazole 
group and 8 (24.2%) patients in the ranitidine group 
who required additional drugs at the end of the study 
period (P=0.186). There were seven patients (3 in the 
pantoprazole group and 4 in the ranitidine group) who 
cannot be reached by telephone follow-up at 24 hours. 
Nine (30%) patients in the pantoprazole group and 12 
(41.4%) patients in the ranitidine group declared to have 
repeated pain (P=0.361). There was also no significant 
difference between the two groups [4 (13.3%) vs. 5 
(17.2%), respectively, P=0.676] seeking for medical aid 
at 24 hours. No adverse effect was noted in both groups.
Variables Pantoprazole Ranitidine
Visual analogue scale 
  Baseline 69.0±23 (61 to 77) 60.9±19 (54 to 68)
  30 minutes 41.4±27 (32 to 51) 32.6±21 (25 to 40)
  60 minutes 29.4±32 (18 to 41) 18.6±19 (12 to 25)
Visual analogue change from
  Baseline
  30 minutes 27.6±28 (18 to 37) 28.3±23 (20 to 37)
  60 minutes 39.6±39 (26 to 53) 42.3±25 (33 to 51)
Table 1. Pain outcomes at 30 and 60 minutes in the two groups 
[mean±SD (95%CI)]
Figure 1. Patient fl ow chart.
Enrollment
Analyzed (n=33)
• Excluded from analysis (give reasons) 
(n=2)
   – One patient diagnozed with cholecystitis 
and one patient with cholangitis
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) 
(n=0)
Analyzed (n=33 )
• Excluded from analysis (give reasons) 
(n=2)
   – One patient diagnosed with cholecystitis 
and one patient with pancreatitis
Allocated to ranitidine group (n=35)
• Received allocated intervention (n=35)
• Did not receive allocated intervention 
(give reasons) (n=0)
Allocated to pantoprazole group (n=35)
• Received allocated intervention (n=35)
• Did not receive allocated intervention 
(give reasons) (n=0)
Lost to follow-up (give reasons) (n=0)
Discontinued intervention (give reasons) 
(n=0) 
Excluded (n=6)
• Not meeting inclusion criteria (n=4)
    – Diagnosed differently from 
dyspepsia at the end of the study
• Declined to participate (n=0)
• VAS score under 20 (n=2)
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DISCUSSION
This study showed that pantoprazole is not better 
than ranitidine in ceasing dyspepsia in patients treated at 
the ED. There are many treatment modalities for peptic 
ulcers and gastritis such as proton pomp inhibitors, H2 
receptor blockers and anti-acids.
[8-10]
 But the results of 
these madalities are not satisfactory in the treatment of 
dyspepsia in the ED. A Cochrane meta-analysis showed 
that PPIs are better than H2 receptor blockers, anti-acids 
and prokinetics in the management of dyspepsia.
[4]
There are few studies comparing the treatment 
modalities for dyspeptic symptoms in the ED. Although 
there are some methodological flaws, Musikatavorn et 
al
[11]
 reported that combination of pantoprazole (80 mg 
IV), anti-acids and anti-spasmolytics (VAS0=64±13 
to VAS60=17±24) was not superior to anti-acids 
and anti-spasmolytics combination (VAS0=64±16 
to VAS60=19±23) at 60 minutes. They also found 
no difference in additional use of a drug between 
pantoprazole and placebo (25% vs. 20%). Despite the 
statistical insignifi cance, the rescue drug rate was 39% in 




compared the oral anti-acids alone 
(n=34) with oral anti-acids and viscous lidocaine 
combination (n=39) in patients with dyspepsia presented 
to the ED. Pain reduction in 11 cm linear analogue scale 
was 9±29 mm in oral anti-acids group and 40±34 mm in 
oral anti-acids and viscous lidocaine combination group 
at 30 minutes (P<0.0001).
Berman et al
[6]
 also found no difference between 
anti-acids, anti-acids+spasmolytics and anti-acids+ 
spasmolytics+oral lidocaine combinations in ceasing 
dyspepsia at 30 minutes. Vilke et al
[12]
 compared 
benzocaine (n=44) and lidocaine (n=38) in patients 
with dyspepsia, and found that after administration of 
oral anti-acids and oral anti-cholinergics there was no 
difference between the two groups at 30 minutes.
There are no adverse effects related to the study 
drugs. PPIs and H2 receptor blocker are genrerally 
accepted as safe drugs. The present study showed 
that pantoprazole and ranitidine are not superior in 
ceasing dyspepsia in the ED, but each is safe to use 
in the ED. Cost might be a matter of choosing the 
appropriate treatment; however whether parenteral drugs 
for dyspepsia are superior to oral drugs such as anti-
acids, local anesthetics and anti-cholinergics or their 
combinations is not clear. Further studies are needed to 
discover the right ways.
Limitations
This study has several limitations. This is a trial with 
a small sample size that is unable to conclude that both 
drugs are equal. A placebo might be added to the study, 
that may clarify the question whether parenteral drugs 
for dyspepsia in the ED are superior to the placebo.
There were no adverse effects in both groups in the 
present study but this finding doesn't mean that these 
drugs have no adverse effects as reported in previous 
trials. But it is troublesome to differentiate these effects 
from dyspepsia or drugs.
Dyspepsia is a symptom rather than a pathological 
diagnosis, and it can be diagnosed after ruling out 
other pathologies. There are no criteria for exclusive 
confirmation of dypepsia in the ED. Hence it may be a 
limitation to our study.
In conclusion, intravenous pantoprazole and 
ranitidine are not superior to each other in ceasing 
dyspeptic symptoms at 30 and 60 minutes in the ED.
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